Das Medi First Prinzip – our compass.
The right to the best possible care.
We address structural gaps in medicinal product supply - with scientific integrity and responsibility that becomes operationally visible.
We regard access to the best possible medical care as a fundamental right. Patients deserve access to therapies that are evidence-based and sustainably viable in everyday practice. We consistently align our processes so that humanity and economic reason form a unity: Precisely managed care counteracts mistreatment, strengthens dignity and autonomy, and promotes the long-term stability of care structures.
A principle for the entire system. Das Medi First Prinzip ist der Taktgeber für die gesamte Gruppe. Es synchronisiert Forschung und Innovation durch den Fokus auf versorgungsrelevante Fragestellungen. Es stärkt Qualität und Verantwortung durch klare Governance, definierte Verantwortlichkeiten und nachvollziehbare Schnittstellen. Und es treibt unsere operative Umsetzung in Pharma und Trade an, weil eine verlässliche Logistik ein integraler Teil einer verantwortbaren Patientenversorgung ist.
Wer mit Medi First arbeitet, entscheidet sich für ein System, das Verantwortung nicht nur beschreibt, sondern in Strukturen übersetzt.
For people. For evidence. For our future.
Our methodology: From supply needs to the specification.
Our reverse-engineering approach starts where care must be effective: with the concrete clinical need of patients. We translate real-world evidence into precise target profiles and build the value chain consistently backwards - from process design to realization. In doing so, we systematically build quality along the entire chain - with multiple quality controls at several points.
This reverse engineering is our structural principle for reproducible and reliable care quality.
Der Medi First Quality Loop zeigt, wie wir Evidenz, Qualitätssicherung und Distribution in einem geschlossenen System zusammenführen.
Vertikale Integration für Präzisionsmedizin:
Ein geschlossener Kreislauf für verlässliche Therapiesicherheit
Patient-centered development
We translate clinical real-world evidence into defined target profiles. From this, we derive the intended cannabinoid/terpene profile as a pharmaceutical specification (reverse engineering)
Proprietary research & genetics
Medi First R&D- und Biotech-Einheiten entwickeln definierte Chemotypen als kontrollierte Ausgangsbasis – abgestimmt mit der Schweizer Forschungsachse (Innuana).
Technological realization
Implementation is carried out via a qualified partner network under GACP/GMP framework conditions - with controlled process parameters and documented interfaces.
Pharmaceutical integrity
As the pharmaceutical entrepreneur, we take responsibility for QA/QP governance: batch testing, specification conformity, and documented release along defined quality processes.
Pharmaceutical logistics
Distribution under a GDP framework: documented handovers, traceability, and controlled supply-chain interfaces to the point of care - operationally connected to the HCP portal.
Evidence as a foundation. Impact as a benchmark
Research forms our organizationally anchored foundation. Every development step of our intentional science follows a clear therapeutic purpose. We invest specifically in knowledge and structures to secure scientifically sound and pharmaceutically stabilized progress that can stand as a robust standard in care.
The touchstone for every decision
We measure our success by the impact achieved: improved care practice, increased decision confidence for healthcare professionals, and stable care structures. Before every project, we ask one question: Does it serve clinical integrity and a responsible implementation? This yardstick protects our direction and the reliability of our system.
